Oncology Stocks As High Risk, High Reward
b"Merck & Co. (MRK) stock price is up over 19% over the past year. Mizuho's Mara Goldstein says that they maintain a buy rating on the MRK stock with a $100 price target. She states that the key takeaway from the cardiovascular event is potential revenue diversification drivers. Goldstein states that a $10B in peak revenue from the cardiovascular pipeline in the mid-2030s would be a strong offset. Also, the SPDR Biotech ETF (XBI) is down 21% year-to-date."